Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry

Projektinformationen

Genome Biologics

ID Finanzhilfevereinbarung: 773750

DOI

10.3030/773750

Projekt abgeschlossen

EK-Unterschriftsdatum 12 Mai 2017

Startdatum 1 Juni 2017

Enddatum 30 September 2017

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

GENOME BIOLOGICS UG
Germany

Periodic Reporting for period 1 - Genome Biologics (Reducing the cost and increasing the speed of preclinical research in the pharmaceutical industry)

Berichtszeitraum: 2017-06-01 bis 2017-09-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Modern drug discovery is inefficient, expensive and risky. Due to high development costs, diseases with smaller market share, such as rare diseases are only satisfied in 5% of cases leaving nearly 350mln people worldwide without any treatments. The Genome Biologics GENIMAPS® and GENISYST® patented drug discovery and testing platform overcomes the inefficiencies of pre-clinical studies with its unique combination of genomics, molecular science and. Using our proprietary Artificial Intelligence-driven Drug-Disease matching platform (GENIMAPS®) and our patented single cell transgenic technology (GENISYST®), the platform reduces drug development or drug repurposing time and costs by a factor of 10, allowing pharmaceuticals companies to bring drug candidates into phase 2/3 clinical trials in as little as 3-6 months, instead of 7-10 years with current methodologies.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Out of the seventeen organisations contacted we have identified a strong interest in our technologies in multiple therapeutic areas, including cardiovascular disease (CVD), Central Nervous System disorders (CNS) and oncology (multiple indications and subtypes).
In addition, we have identified potential interest in our technologies for lifestyle diseases, including Non-Alcoholic Fatty Liver disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), obesity and diabetes, which we are currently following up with one of the potential trial partners for a future project application in Phase 2. Investigation of the regulatory environment within Europe has not revealed any issues apart from the requirement to obtain biosafety approval from the appropriate government biosafety authorities. We have provided price indications and quotations to a number of companies and the response has been very good. All companies see the benefit of our technologies outweighing the cost and therefore are not particularly sensitive to the cost factor. These and other analyses are summarised in the Phase 1 final report.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

In combining the power of our GENIMAPS and GENISYST platform, we have identified and developed 2 promising therapeutic agents for heart failure which demonstrated efficacy in restoring heart function and reducing mortality in rodent pre-clinical studies. If successful in downstream clinical trials, these compounds have the potential to alleviate heart disease in humans and increase life quality and expectancy. In parallel, Genome Biologics have discovered a potential for the repurposing of 5 FDA-approved compounds for the treatment of specific sub-types of prostate cancer in humans. Pending further studies, these compounds could contribute to better treatment options for prostate cancer.

Genome Biologics Technology Advantage